Quince Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

• Quince Therapeutics, Inc. showed an increase of +105.9% in Cash And Cash Equivalents At Carrying Value from 2018 to 2019.
• This data is from Quince Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2020.
• XBRL data for this metric is available from 2018 to 2019 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2018: $4.40 million | Q2 2018: $77.47 million | Q3 2018: $27.29 million | Q1 2019: $20.63 million | Q2 2019: $44.31 million | Q3 2019: $44.74 million | Q4 2019: $51.21 million | Q1 2020: $85.61 million | Q2 2020: $66.16 million | Q3 2020: $64.25 million | Q4 2024: $6.21 million | Q1 2025: $7.77 million | Q2 2025: $16.83 million | Q3 2025: $6.45 million.
• Historical annual values: Fiscal year 2019: $51.21 million | Fiscal year 2018: $24.87 million.
• Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: August 10, 2026